Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03627767 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,235
- Enrollment target
NCT03627767 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,235 participants.
The verdict
NCT03627767, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,235 participants
- Enrollment target
Study Summary
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
Interventions
- DRUG Placebo
- DRUG PF-04965842 100 mg
- DRUG PF-04965842 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,235 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03627767
The ClinicalTrials.gov registry entry for NCT03627767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03627767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03627767 about?
NCT03627767 is a clinical study titled "Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects". B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will b...
What is the current status of trial NCT03627767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,235 participants. The study started on 2018-06-11. Estimated completion is 2020-10-07.
What interventions are being tested in trial NCT03627767?
The interventions under investigation include: Placebo (DRUG), PF-04965842 100 mg (DRUG), PF-04965842 200 mg (DRUG).
Who is sponsoring clinical trial NCT03627767?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.